Key Takeaways
- Global net sales of DARZALEX® (daratumumab) in 2024 totaled $11.67 billion.
- Genmab earns royalties on sales through its exclusive worldwide licensing agreement with Johnson & Johnson (J&J).
- Sales breakdown: $6.59 billion in the U.S. and $5.08 billion internationally.
Genmab A/S announced that worldwide net sales of DARZALEX® (daratumumab), including the subcutaneous (SC) formulation DARZALEX FASPRO®, reached an impressive $11.67 billion in 2024. Sales data, reported by Johnson & Johnson (J&J), reflects strong market performance, with $6.59 billion in sales generated in the U.S. and $5.08 billion from international markets.
Genmab receives royalties from J&J on both the intravenous (IV) and subcutaneous formulations of DARZALEX under a global licensing agreement. This long-standing partnership highlights the transformative potential of daratumumab in improving patient outcomes across multiple indications, including multiple myeloma.
Expanding Reach Through Innovative Antibody Science
Since its initial approval, DARZALEX has established itself as a cornerstone therapy in oncology, particularly for multiple myeloma. By integrating innovative antibody science, such as daratumumab and hyaluronidase-fihj for subcutaneous administration, Genmab and J&J have expanded access to this life-saving treatment.
Sarah K. Emond, MPP, CEO of ICER, emphasized the significance of pricing tied to clinical value: “Aligning innovative treatments with affordability ensures fair access for patients while sustaining the healthcare ecosystem.” DARZALEX’s consistent growth underscores its clinical efficacy, patient accessibility, and global market penetration.
About Genmab: Pioneers in Antibody Therapeutics
Founded in 1999, Genmab has remained at the forefront of antibody science for over two decades. With a focus on innovative and differentiated therapeutics, the company’s proprietary platforms include bispecific T-cell engagers, antibody-drug conjugates, and next-generation immune checkpoint modulators.
Headquartered in Copenhagen, Denmark, Genmab has an international presence spanning North America, Europe, and Asia Pacific. By 2030, its vision is to transform the lives of patients with cancer and other serious diseases through KYSO® antibody medicines.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
